Updated on 2021/12/06

写真a

 
KURIMOTO Keisuke
 
Organization
Nagoya University Hospital Assistant professor of hospital
Title
Assistant professor of hospital

Degree 1

  1. PhD ( 2019.3   Nagoya University ) 

Research Interests 4

  1. clinical oncology

  2. hepatobiliary and pancreatic surgery

  3. gastroenterological surgery

  4. molecular biology

Research Areas 2

  1. Life Science / Tumor biology  / clinical oncology

  2. Life Science / Digestive surgery  / hepatobiliary and pancreatic surgery

Research History 3

  1. Nagoya University   Graduate School of Medicine   Assistant Professor

    2019.4

  2. Ministry of Health, Labour and Welfare

    2018.4 - 2019.3

  3. Ministry of Health, Labour and Welfare

    2016.7 - 2018.3

 

Papers 21

  1. Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy

    Sunagawa Yuki, Hayashi Masamichi, Yamada Suguru, Tanabe Hiroshi, Kurimoto Keisuke, Tanaka Nobutake, Sonohara Fuminori, Inokawa Yoshikuni, Takami Hideki, Kanda Mitsuro, Tanaka Chie, Nakayama Goro, Koike Masahiko, Kodera Yasuhiro

    CLINICAL EPIGENETICS   Vol. 13 ( 1 ) page: 172   2021.12

     More details

    Language:Japanese   Publisher:Clinical Epigenetics  

    Background: Pancreatic cancer is one of the lethal cancers among solid malignancies. Pathological diagnosis of surgical margins is sometimes unreliable due to tissue shrinkage, invisible field cancerization and skipped lesions like tumor budding. As a result, tumor recurrences sometimes occur even from the pathologically negative surgical margins. Methods: We applied molecular surgical margin (MSM) analysis by tissue imprinting procedure to improve the detection sensitivity of tiny cancerous cells on the surgical specimen surface after pancreatoduodenectomy. Surgical specimens were collected from 45 pancreatic cancer cases who received subtotal stomach preserving pancreatoduodenectomy at Nagoya University Hospital during 2017–2019. Quantitative methylation-specific PCR (QMSP) of the original methylation marker panel (CD1D, KCNK12, PAX5) were performed and analyzed with postoperative survival outcomes. Results: Among 45 tumors, 26 cases (58%) were QMSP-positive for CD1D, 25 (56%) for KCNK12 and 27 (60%) for PAX5. Among the 38 tumors in which at least one of the three markers was positive, CD1D-positive cancer cells, KCNK12-positive cancer cells, and PAX5-positive cancer cells were detected at the surgical margin in 8 cases, 7 cases and 10 cases, respectively. Consequently, a total of 17 patients had at least one marker detected at the surgical margin by QMSP, and these patients were defined as MSM-positive. They were associated with significantly poor recurrence-free survival (p = 0.002) and overall survival (p = 0.005) than MSM-negative patients. Multivariable analysis showed that MSM-positive was the only significant independent factor for worse recurrence-free survival (hazard ratio: 3.522, 95% confidence interval: 1.352–9.179, p = 0.010). On the other hand, a significant proportion of MSM-negative cases were found to have received neoadjuvant chemotherapy (p = 0.019). Conclusion: Pancreatic cancer-specific methylation marker panel was established to perform MSM analysis. MSM-positive status might represent microscopically undetectable cancer cells on the surgical margin and might influence the postoperative long-term outcomes.

    DOI: 10.1186/s13148-021-01165-8

    Web of Science

    Scopus

    PubMed

  2. 膵癌に対する術前AGRと臨床病理学的因子や予後に関する検討

    小林 大悟, 林 真路, 加藤 吉康, 栗本 景介, 田中 伸孟, 砂川 祐輝, 園原 史訓, 猪川 祥邦, 高見 秀樹, 小寺 泰弘

    日本消化器外科学会総会   Vol. 76回   page: P129 - 4   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

  3. 右側肝円索に合併した胆嚢癌の1例

    鈴木 雄之典, 猪川 祥邦, 栗本 景介, 田中 伸孟, 園原 史訓, 高見 秀樹, 林 真路, 中山 吾郎, 小池 聖彦, 小寺 泰弘

    日本消化器外科学会総会   Vol. 76回   page: P126 - 6   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

  4. miR-23b-3p Plays an Oncogenic Role in Hepatocellular Carcinoma. International journal

    Masamichi Hayashi, Suguru Yamada, Keisuke Kurimoto, Hiroshi Tanabe, Sho Hirabayashi, Fuminori Sonohara, Yoshikuni Inokawa, Hideki Takami, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Masahiko Koike, Yasuhiro Kodera

    Annals of surgical oncology   Vol. 28 ( 6 ) page: 3416 - 3426   2021.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Reports show miR-23b to be a cancer-related biomarker in various cancer types. Interestingly, it has a dual role of oncogenic and tumor-suppressive functions, depending on the cancer type. This study focused on the unknown association of miR-23b-3p with hepatocellular carcinoma (HCC). METHODS: Expression of miR-23b-3p was measured in nine HCC cell lines and 125 resected human HCC samples by TaqMan microRNA assays. To detect its downstream target, miR-23b-3p mimic and inhibitor constructs were transfected and analyzed. RESULTS: HepG2, a high miR-23b-3p-expressing cell line, was transfected with a miR-23b-3p inhibitor construct, whereas SK-Hep1, a low miR-23b-3p-expressing cell line, was transfected with a mimic construct. Proliferation of HCC cells was activated by miR-23b-3p overexpression and diminished by its knockdown. Then, 125 clinical HCC samples were examined to measure miR-23b-3p expression. Tumor expression of miR-23b-3p was upregulated in 48 cases (38%) and downregulated in 77 cases (62%). The upregulated cases were correlated with elderly patients (P = 0.015). These patients also showed significantly poor overall survival [hazard ratio (HR), 3.10; 95% conflidence interval (CI), 1.57-6.29; P = 0.001] in a multivariate analysis. Furthermore, mitochondrial metabolism-related genes (MICU3 and AUH) were detected as specific binding targets. CONCLUSION: The study showed that miR-23b-3p functions as an oncogenic microRNA in HCC cell lines. Its overexpression in resected HCC tissues was a significant prognostic factor of overall survival. Both MICU3 and AUH may be candidate gene targets of miR-23b-3p.

    DOI: 10.1245/s10434-020-09283-y

    Web of Science

    Scopus

    PubMed

  5. パンデミック下における外科卒前教育の工夫

    高見 秀樹, 小池 聖彦, 鈴木 雄之典, 栗本 景介, 田中 伸孟, 柴田 雅央, 園原 史訓, 武内 大, 猪川 祥邦, 服部 憲史, 林 真路, 神田 光郎, 田中 知恵, 山田 豪, 中山 吾郎, 菊森 豊根, 藤原 道隆, 小寺 泰弘

    日本外科学会定期学術集会抄録集   Vol. 121回   page: SP - 7   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

  6. 転移性肝腫瘍に対する至適治療戦略 術前化学療法の可否につき考える

    林 真路, 山田 豪, 高見 秀樹, 猪川 祥邦, 園原 史訓, 田中 伸孟, 栗本 景介, 砂川 祐輝, 加藤 吉康, 中川 暢彦, 鈴木 雄之典, 山中 雅也, 清水 大, 服部 憲史, 神田 光郎, 田中 千恵, 中山 吾郎, 小池 聖彦, 小寺 泰弘

    日本外科学会定期学術集会抄録集   Vol. 121回   page: SF - 5   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

  7. Genome-wide identification and characterization of circular RNA in resected hepatocellular carcinoma and background liver tissue. International journal

    Yuki Sunagawa, Suguru Yamada, Fuminori Sonohara, Keisuke Kurimoto, Nobutake Tanaka, Yunosuke Suzuki, Yoshikuni Inokawa, Hideki Takami, Masamichi Hayashi, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Masahiko Koike, Yasuhiro Kodera

    Scientific reports   Vol. 11 ( 1 ) page: 6016 - 6016   2021.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Circular RNA (circRNA) is a type of non-coding RNA known to affect cancer-related micro RNAs and various transcription factors. circRNA has promise as a cancer-related biomarker because its circular structure affords high stability. We found using high-throughput sequencing that seven candidate circRNAs (hsa_circ_0041150, hsa_circ_0025624, hsa_circ_0001020, hsa_circ_0028129, hsa_circ_0008558, hsa_circ_0036683, hsa_circ_0058087) were downregulated in HCC. The expression of these circRNAs was examined by quantitative PCR in 233 sets of HCC and matched background normal liver tissues, and correlations between candidate circRNA expression and prognosis were evaluated. The results of quantitative PCR showed that expression of hsa_circ_0041150, hsa_circ_0001020 and hsa_circ_0008558 was significantly lower in HCC than in background normal liver tissues. Kaplan-Meier analysis revealed that low expression of hsa_circ_0001020, hsa_circ_0036683, and hsa_circ_0058087 was associated with poor recurrence-free (RFS) and overall survival (OS) in HCC. Additionally, multivariate analysis revealed that low hsa_circ_0036683 expression was a significant prognostic factor, independent from other clinicopathological features, for inferior RFS and OS. There was no significant association between the expression of these circRNAs and hepatitis B/C status or cirrhosis. This study therefore identified circRNAs as potential prognostic markers for patients who undergo curative surgery for HCC and highlighted hsa_circ_0036683 as the most useful biomarker.

    DOI: 10.1038/s41598-021-85237-y

    Web of Science

    Scopus

    PubMed

  8. Age-Related Differences in the Prognosis of Pancreatic Cancer According to Perioperative Systemic Therapy. International journal

    Fuminori Sonohara, Suguru Yamada, Keisuke Kurimoto, Yoshikuni Inokawa, Hideki Takami, Masamichi Hayashi, Dai Shimizu, Norifumi Hattori, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Masahiko Koike, Tsutomu Fujii, Yasuhiro Kodera

    Pancreas   Vol. 50 ( 1 ) page: 37 - 46   2021.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: In this study, we retrospectively assessed the feasibility and prognostic efficacy of perioperative chemo(radio)therapy for pancreatic cancer (PC) patients according to age. METHODS: A total of 556 consecutive patients who underwent curative-intent pancreatectomy for PC between 2000 and 2018 were enrolled. RESULTS: Of the 556 patients who underwent resection, 95 (17%) were elderly (age, ≥75 years). Postoperative complications did not significantly differ between the 2 age groups, and postoperative prognoses were also similar (recurrence-free survival [RFS], P = 0.68; overall survival [OS], P = 0.28). In this cohort, 103 patients (19%) underwent preoperative chemo(radio)therapy, and 417 (77%) underwent postoperative chemotherapy. Perioperative therapy was found to be significantly beneficial for younger patients (preoperative therapy: RFS, P = 0.006; OS, P < 0.001; postoperative therapy: RFS, P < 0.001; OS, P < 0.001). Conversely, no significant survival benefit of perioperative therapy was found for the elderly (preoperative therapy: RFS, P = 0.28; OS, P = 0.44; postoperative therapy: RFS, P = 0.77; OS, P = 0.08). CONCLUSIONS: This study demonstrated that, although perioperative therapy is feasible for selected elderly patients with PC, this approach might not be as beneficial as it is for younger PC patients.

    DOI: 10.1097/MPA.0000000000001712

    Web of Science

    Scopus

    PubMed

  9. Difference Between Educational Law and the Present Status of Continuing Education of High School-Aged Patients with Cancer

    Ozawa Miwa, Maeda Naoko, Mori Makiko, Kurimoto Keisuke, Tsuchiya Miyako, Horibe Keizo

    PEDIATRIC BLOOD & CANCER   Vol. 67   2020.12

     More details

    Language:Japanese  

    Web of Science

  10. ゲノムワイドアプローチによる肝細胞癌関連circRNAの探索

    砂川 祐輝, 山田 豪, 園原 史訓, 栗本 景介, 猪川 祥邦, 高見 秀樹, 林 真路, 中山 吾郎, 小池 聖彦, 小寺 泰弘

    日本消化器外科学会総会   Vol. 75回   page: P219 - 4   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

  11. 膵臓 化学療法

    砂川 祐輝, 山田 豪, 山中 雅也, 鈴木 雄之典, 中川 暢彦, 加藤 吉康, 田中 伸孟, 栗本 景介, 園原 史訓, 猪川 祥邦, 高見 秀樹, 林 真路, 神田 光郎, 田中 千恵, 中山 吾郎, 小池 聖彦, 小寺 泰弘

    日本消化器外科学会雑誌   Vol. 53 ( Suppl.2 ) page: 311 - 311   2020.11

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

  12. 大腸癌初回肝転移手術後の早期再発予測因子の検討

    林 真路, 山田 豪, 高見 秀樹, 猪川 祥邦, 園原 史訓, 砂川 祐輝, 田中 伸孟, 栗本 景介, 加藤 吉康, 中川 暢彦, 鈴木 雄之典, 神田 光郎, 田中 千恵, 小林 大介, 中山 吾郎, 小池 聖彦, 藤原 道隆, 小寺 泰弘

    日本外科学会定期学術集会抄録集   Vol. 120回   page: DP - 4   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

  13. 膵頸部癌における臨床病理学的特徴

    栗本 景介, 山田 豪, 鈴木 雄之典, 中川 暢彦, 加藤 吉康, 田中 伸孟, 砂川 祐輝, 園原 史訓, 猪川 祥邦, 高見 秀樹, 林 真路, 神田 光郎, 田中 千恵, 中山 吾郎, 小池 聖彦, 小寺 泰弘

    日本外科学会定期学術集会抄録集   Vol. 120回   page: SF - 3   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

  14. 膵頭部癌における周術期輸血の長期予後に対する影響

    田中 伸孟, 山田 豪, 栗本 景介, 園原 史訓, 猪川 祥邦, 高見 秀樹, 林 真路, 中山 吾郎, 小池 聖彦, 小寺 泰弘

    日本外科学会定期学術集会抄録集   Vol. 120回   page: SF - 3   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

  15. 膵頭十二指腸切除術施行膵癌患者における周術期メインおよびリパクレオン投与の安全性と有用性

    中川 暢彦, 山田 豪, 多代 充, 栗本 景介, 園原 史訓, 清水 大, 猪川 祥邦, 高見 秀樹, 服部 憲史, 林 真路, 神田 光郎, 田中 千恵, 小林 大介, 中山 吾郎, 小池 聖彦, 藤原 道隆, 小寺 泰弘, 小寺 泰弘

    日本外科学会定期学術集会抄録集   Vol. 120回   page: DP - 5   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

  16. 膵癌に対する膵頭十二指腸切除術の分子生物学的なsurgical marginの評価

    砂川 祐輝, 山田 豪, 林 真路, 高見 秀樹, 猪川 祥邦, 園原 史訓, 栗本 景介, 田中 伸孟, 加藤 吉康, 中川 暢彦, 鈴木 雄之典, 神田 光郎, 田中 千恵, 小林 大介, 中山 吾郎, 小池 聖彦, 藤原 道隆, 小寺 泰弘

    日本外科学会定期学術集会抄録集   Vol. 120回   page: SF - 2   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

  17. 進行膵癌におけるオリゴメタスタシス症例の検討

    林 真路, 山田 豪, 高見 秀樹, 園原 史訓, 猪川 祥邦, 田中 伸孟, 加藤 吉康, 中川 暢彦, 栗本 景介, 鈴木 雄之典, 山中 雅也, 小寺 泰弘

    膵臓   Vol. 35 ( 3 ) page: A304 - A304   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本膵臓学会  

  18. 胃原発mixed adenoneuroendocrine carcinomaの1例

    荘加 道太, 清水 大, 栗本 景介, 園原 史訓, 猪川 祥邦, 高見 秀樹, 服部 憲史, 林 真路, 神田 光郎, 田中 千恵, 小林 大介, 山田 豪, 中山 吾郎, 小池 聖彦, 小寺 泰弘

    日本消化器病学会東海支部例会プログラム抄録集   Vol. 131回   page: 59 - 59   2019.11

     More details

    Language:Japanese   Publisher:日本消化器病学会-東海支部  

  19. 日本のAYA世代のがん対策の方向性を読み解く Reviewed

    栗本 景介, 堀部 敬三, 園原 史訓, 猪川 祥邦, 高見 秀樹, 林 真路, 神田 光郎, 小林 大介, 田中 千恵, 山田 豪, 中山 吾郎, 小池 聖彦, 清水 千佳子, 高橋 義行, 小寺 泰弘

    日本癌治療学会学術集会抄録集   Vol. 57回   page: P166 - 5   2019.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

  20. Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy. Reviewed

    Niwa Y, Yamada S, Sonohara F, Kurimoto K, Hayashi M, Tashiro M, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y

    Journal of translational medicine   Vol. 17 ( 1 ) page: 1   2019.1

     More details

  21. PAX5 gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma Reviewed

    Keisuke Kurimoto, Masamichi Hayashi, Rafael Guerrero-Preston, Masahiko Koike, Mitsuro Kanda, Sho Hirabayashi, Hiroshi Tanabe, Nao Takano, Naoki Iwata, Yukiko Niwa, Hideki Takami, Daisuke Kobayashi, Chie Tanaka, Suguru Yamada, Goro Nakayama, Hiroyuki Sugimoto, Tsutomu Fujii, Michitaka Fujiwara, Yasuhiro Kodera

    EPIGENETICS   Vol. 12 ( 10 ) page: 865 - 874   2017

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:TAYLOR & FRANCIS INC  

    Therapeutic strategies for esophageal cancer largely depend on histopathological assessment. To select appropriate treatments of individual patients, we examined the background molecular characteristics of tumor malignancy and sensitivity to multidisciplinary therapy. Seventy-eight surgically-resected esophageal squamous cell carcinoma (ESCC) cases during 2001-2013 were examined. PAX5, a novel gene methylation marker in ESCC, was evaluated in the specimens, as methylation of this gene was identified as an extremely tumor-specific event in squamous cell carcinogenesis of head and neck. PAX5 methylation status was evaluated by quantitative MSP (QMSP) assays. Mean QMSP value was 15.7 (0-136.3) in ESCCs and 0.3 (0-8.6) in adjacent normal tissues (P &lt; 0.001). The 78 cases were divided into high QMSP value (high QMSP, n D 26) and low QMSP value (low QMSP, n D 52). High QMSP cases were significantly associated with downregulated PAX5 expression (P D 0.040), and showed significantly poor recurrencefree survival [Hazard Ratio (HR) D 2.84; P D 0.005; 95% Confidence Interval (CI): 1.39-5.81] and overall survival (HR D 3.23; P D 0.002; 95% CI: 1.52-7.01) in multivariable analyses with histopathological factors. PAX5-knockdown cells exhibited significantly increased cell proliferation and cisplatin resistance. PAX5 gene methylation can predict poor survival outcomes and cisplatin sensitivity in ESCCs and could be a useful diagnostic tool for cancer therapy selection.

    DOI: 10.1080/15592294.2017.1365207

    Web of Science

    Scopus

    PubMed

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 1

  1. 高齢消化器癌手術症例における術後自立度低下に関するリスク評価と介入の有効性の検討

    Grant number:21K11620  2021.4 - 2024.3

    科学研究費助成事業  基盤研究(C)

    田中 千恵, 神田 光郎, 渡邊 一久, 小寺 泰弘, 室谷 健太, 栗本 景介, 藤原 道隆

      More details

    Authorship:Coinvestigator(s) 

    本研究は,消化器癌における様々な術式の自立度への影響と複数の診療科を含む多職種横断的な介入の効果を包括的に把握し,高齢者に対する癌治療のエビデンス構築の一助となるデータを構築することを目的とする。まず,術前後の自立度の変化について調査票と血清バイオマーカー値の両面から評価する。次に,自立度が低下する患者については,老年科専門医・リハビリテーション・栄養サポートチームによる介入で機能維持を図り,ひいては,事前に自立度が低下する群を予測し,予防的介入が可能となることを見込む。